Loading
Everything OnCo dates to 1953: 10 entries, 4 landmarks, 3 technologies, 2 approvals and 1 journal founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
10 dated entries in OnCo fall in 1953: 4 landmarks, 3 technologies, 2 approvals and 1 journal founded.
Of those, 10 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Acute lymphoblastic leukaemia, combination maintenance therapy
ALL, choriocarcinoma, and later osteosarcoma, breast, head and neck, lung, lymphoma, mycosis fungoides
The history entries editors wrote on cancer records: the dated turning points of each disease.
Medulloblastoma. First cures.
Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)
Langerhans cell histiocytosis (LCH)
Single-system Langerhans cell histiocytosis (bone, skin or one other organ)
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on journal records.
Elsevier (Academic Press)